Following Brexit, the funding infrastructure for new buyout funds in the UK has broken down. These new managers are now struggling to find anchor investors and offer an opportunity to the private sector to step in and secure attractive returns. The post The Opportunity being Missed in UK Healthcare Buyouts appeared first on MedCity News.
Healthcare supplies have a direct correlation to the safety and national security of Americans as any disruption to availability jeopardizes the health of our nation. Americans cannot forego access to lifesaving medications. The post The National Security Stakes of Pharmaceutical Tariffs appeared first on MedCity News.
A review of the 2025 Medicare Advantage plans available for individual enrollment shows that the total number of plans declined by 7% (from 3,959 to 3,699). The average Medicare beneficiary will have the option of 34 Medicare Advantage prescription drug (MA-PD) plans in 2025, just 2 fewer than the 36 options available in 2024. Since…
In a series of articles to promote INVEST 2025 in Chicago April 29-30, we are highlighting investment insights and perspectives in the runup to the boutique event for traditional and strategic healthcare investors and startups. Register today! The post Springboard Enterprises Executive-in-Residence Shares Advice to Startups appeared first on MedCity News.
By MATTHEW HOLT I was having a fight on Twitter this week and it hit me. America 2024 is Japan 1989. The topic of the fight was right-wing VC Peter Thiel. In 2001 he put a ton of Paypal stock allegedly worth less than $2,000 into a Roth IRA. The Roth IRA was designed so…
Jazz Pharmaceuticals’ acquisition of Chimerix brings a drug that could become the first approved therapy for a rare and aggressive form of brain cancer affecting children and young adults. An FDA decision for the molecule, dordaviprone, is expected in August. The post First-in-Class Brain Cancer Drug Strikes a Chord With Jazz Pharma to the Tune…
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
This brief describes four key federal vaccine advisory committees and discusses policy issues and questions they currently face. The four committees are the Vaccines and Related Biological Products Advisory Committee (VRBPAC) at the Food and Drug Administration (FDA); the Advisory Committee on Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC); the…
Verdiva Bio’s once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences. The post Metabolic Meds Startup Verdiva Launches With $410M and a Weekly Oral GLP-1 Drug appeared first on MedCity News.
This near-constant level of unpredictability forces us to ask a tricky question: how can biopharma companies stay ahead? The answer, as to many of the tricky questions of our time, lies in having a clear and authentic mission to act as a guiding lighthouse in the turbulent waters of change. The post Maintaining Composure in…